Guardant Health (NASDAQ: GH) shares Q3 2025 financial results release

Rhea-AI Filing Summary

Guardant Health, Inc. furnished an update on its latest results by submitting a Form 8-K. On October 29, 2025, the company issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025, and attached the full text of that release as Exhibit 99.1. The disclosure clarifies that this information, including the exhibit, is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.

0001576280false00015762802025-10-292025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 29, 2025

GUARDANT HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38683

45-4139254

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

3100 Hanover Street

Palo Alto, California 94304

(Address of principal executive offices) (Zip Code)

855-698-8887

(Registrant’s telephone number, include area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, $0.00001 par value per share			GH			The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 2.02 Results of Operations and Financial Condition.

On October 29, 2025, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release of Guardant Health, Inc., dated October 29, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						GUARDANT HEALTH, INC.
Date:			October 29, 2025			By:			/s/ Michael Bell
									Michael Bell
									Chief Financial Officer
									(Principal Accounting Officer and Principal Financial Officer)

FAQ

What did Guardant Health (GH) report in its latest Form 8-K?

Guardant Health filed a Form 8-K to furnish a press release announcing its financial results for the fiscal quarter ended September 30, 2025, which is included as Exhibit 99.1.

Which period do the Guardant Health (GH) results in this 8-K cover?

The results discussed in the furnished press release relate to Guardant Health’s fiscal quarter ended September 30, 2025.

How did Guardant Health provide its Q3 2025 financial results?

The company provided its Q3 2025 financial results through a press release dated October 29, 2025, which is attached to the Form 8-K as Exhibit 99.1.

Is the Guardant Health (GH) earnings press release considered filed with the SEC?

No. The company states that the information in this Form 8-K, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

What exhibits are included with this Guardant Health (GH) Form 8-K?

The Form 8-K includes Exhibit 99.1, the Guardant Health press release dated October 29, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Guardant Health (GH) Form 8-K for the company?

The Form 8-K was signed on behalf of Guardant Health, Inc. by Michael Bell, who serves as Chief Financial Officer and as the principal accounting and financial officer.